In 2014, Gregory I. Frost, Ph.D. earned $1.82M in total compensation at Halozyme Therapeutics, including $593.39K salary and $1.00M bonus. Most recently acquired 2,000 shares in Aug 2012. Currently holds stock worth $228.10M. Led Halozyme Therapeutics as CEO for 3 years.
Compensation History
Annual executive compensation data for Gregory I. Frost, Ph.D., including salary, bonuses, and stock awards.
Year
2014
Total Compensation
$1.82M
Salary
$593.39K
Bonus
$1.00M
Other
$227.88K
Salary
$593.39KBoard Justification
The compensation philosophy is designed to align the interests of executives with those of stockholders, focusing on performance-based metrics and competitive compensation to attract and retain top talent.
Bonus
$1.00MBoard Justification
This bonus was intended to replace an equivalent bonus that Dr. Frost would have earned from his former employer.
Other Compensation
$227.88KBoard Justification
Includes reimbursement of relocation expenses and contributions to the 401(k) plan.
Restricted Stock
Board Justification
No stock awards vested in 2014 as the focus was on cash compensation and bonuses.
Performance Metrics
Performance metrics include revenue growth, operational efficiency, and strategic partnerships.
Gregory I. Frost, Ph.D.
Founder and Ex-CEO of Halozyme Therapeutics
Education
Not specified
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
Born
January 1, 1971 - 54 years ago
CEO of Halozyme Therapeutics for
3 years 1 month (Dec 2010 - Jan 2014)
Previous Experience
Co-founder of Halozyme Therapeutics, Inc.
Other Halozyme Therapeutics CEOs
Holdings
Track Gregory I. Frost, Ph.D.'s stock holdings and portfolio value over time.
Insider Trading
Gregory I. Frost, Ph.D.'s recent stock transactions, purchases, and sales filed with the SEC.
$11.00K
HALO at $5.50/share
Aug 13, 2012
Purchase
$35.04K
HALO at $5.84/share
Aug 9, 2011
Purchase
Rivals
Compare Gregory I. Frost, Ph.D. with competitor CEOs and industry peers.